💬In plain words
What the trial is, and whether it could suit you
Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that appears to behave like a slowly growing cancer. Since clinical progression is very slow, new blood tests have been used to speed the time required to find safe and effective medications. A large National Institute of Health study called MILES showed that sirolimus (also known as Rapamycin) improved lung function in individuals with LAM. Since most individuals with LAM and impaired lung function are now on sirolimus, future studies may prove more difficult. Laboratory studies suggested that Imatinib mesylate (imatinib), an FDA-approved drug for leukemia, initiates LAM cell death. A pilot trial with imatinib titled "Imatinib Mesylate for the treatment of Lymphangioleiomyomatosis" - (LAMP-1) was funded by the Department of Defense in 2016, and documented (1) the safety of use of tyrosine kinase inhibitors in patients with LAM
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* Women 18 through 64 years of age (inclusive)
* Pulmonary Function Test (PFT) with following criteria:
1. DLCO \>20% predicted and FVC \<90% OR
2. Post bronchodilator FEV1 between 30% and 90% predicted.
* Confirmed or possible diagnosis of LAM
* Willing to avoid grapefruit juice and St. John's wort while in the study
* Able and willing to comply with the study procedures
Exclusion Criteria:
* Women who have or will undergo a transplant
* Women who will undergo surgery
* Women who are currently pregnant or plan on a pregnancy
* Women who are currently breast feeding or lactating
* Dementia or other cognitive dysfunction that, in the opinion of the investigator, would prevent the participant from consenting to the study or completing study procedures
* Currently taking any of the following medications:
* Antifungal Medications: Ketoconazole; Itraconazole ; Voriconazole.
* Antibiotics for bacterial infections: Clarithromycin.
* Analgesics to treat headaches/migraines: Dihydroergotamine; Dihydroergotamine intranasal
* Antiretroviral protease inhibitors used in human immunodeficiency virus (HIV) infections: Atazanavir ; Nelfinavir; Indinavir; Ritonavir; Saquinavir
* Anti-epileptic or seizure medications: Carbamazepine, Fosphenytoin; Oxcarbamazepine; Phenobarbital ; Phenytoin; Primidone
* Anti-depressant medications: Nefazodone; St. John's wort
* Targeted cancer drugs: Regorafenib; Venetoclax ; Cobimetinib
* Ivabradine (used to treat chronic heart failure); Telithromycin (used to treat community acquired pneumonia); Lomitapide (treatment of familial hypercholesterolemia); Lonafarnib (Hutchinson-Gilford progeria syndrome); conivaptan (treat low sodium levels); flibanserin (management of hypoactive sexual desire disorder (HSDD)); Naloxegol (opioid-induced constipation); Warfarin (prevent blood clots); Lurasidone (schizophrenia and bipolar depression); Eliglustat (treatment of Gaucher's disease).
* Non English speaking, illiterate, or other vulnerable persons will not be included among study subjects.
* Any condition that in the opinion of the investigator might adversely influence the study outcome.
HealthTeky